Since multiple targeted tyrosine kinase inhibitors have been developed to specifically target the BCR/ABL mutation in leukemia/lymphoma patients, diagnosis of the subtype of the leukemia/lymphoma with the BCR/ABL mutation will be very important in regarding the patient's treatment. This evidence concerns the gene ABL1 and lymphoma.